Drug Profile

DSP 3456

Alternative Names: DSP-3456

Latest Information Update: 02 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sumitomo Pharma
Class Antidepressants; Small molecules
Mechanism of Action Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 3 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

02 Dec 2025 Phase-I development in Treatment-resistant depressive disorder is ongoing in USA (Sumitomo Pharma pipeline, December 2025)
28 Jun 2025 No recent reports of development identified for phase-I development in Treatment-resistant depressive disorder in USA
24 May 2022 Phase-I clinical trials in Treatment-resistant depressive disorder in USA (unspecified route) prior to May 2022 (Sumitomo Pharma pipeline, May 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com